# DECIPHER-GASTRO (liquid biopsy for oesophageal, gastric and colorectal cancer, Shandong)

Source: https://onco.cc/trials/decipher-gastro/  
OnCo record `decipher-gastro` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Chinese screening cohort testing one blood test for three digestive cancers that are common in Shandong.

## Summary

DECIPHER-GASTRO (NCT07106424) is an observational study sponsored by Shandong Cancer Hospital and Institute. It is a liquid biopsy early screening cohort for gastrointestinal cancers.

The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 4,000 participants, a start on 10 September 2024 and primary completion expected on 10 September 2028.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-29
- Also known as: DECIPHER-GASTRO
- Registry id: NCT07106424
- Phase: observational
- Setting: Adults in Shandong Province, China, in a screening cohort for oesophageal, gastric and colorectal cancer by liquid biopsy
- Sponsor: Shandong Cancer Hospital and Institute
- Enrolled: 4000

## Sources

- ClinicalTrials.gov NCT07106424: https://clinicaltrials.gov/study/NCT07106424

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)

---
JSON: https://onco.cc/api/v1/entities/decipher-gastro.json